---
title: "Climb Bio reports translational model, Phase 1 safety and dose data for CLYM116"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288854182.md"
description: "Climb Bio reported translational PK/PD modeling and initial Phase 1 safety data for its anti-APRIL antibody, CLYM116. The model suggests potential for less-frequent dosing based on dose-dependent IgA suppression. In a preliminary study of 49 healthy volunteers, single doses up to 320 mg showed no serious adverse events or discontinuations, with only mild, self-resolving side effects. These findings support the global Phase 1 strategy involving approximately 80 volunteers to determine optimal dosing."
datetime: "2026-06-05T11:23:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288854182.md)
  - [en](https://longbridge.com/en/news/288854182.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288854182.md)
---

# Climb Bio reports translational model, Phase 1 safety and dose data for CLYM116

**Climb Bio announced translational PK/PD modeling and initial Phase 1 safety data for anti-APRIL antibody CLYM116, supporting less‑frequent dosing potential.**

**Key Highlights:**

-   Translational PK/PD model from pooled NHP data projects human exposure and dose‑dependent IgA suppression, implying potential for less‑frequent dosing.
-   Literature analysis shows strong correlation in IgA reduction between NHP and healthy volunteer studies, supporting translational relevance.
-   Global Phase 1 strategy uses ~80 healthy volunteers across ex‑China and China (25–640 mg) to build population PK data for dose selection.
-   Preliminary safety in 49 volunteers (single doses up to 320 mg or placebo) showed no SAEs, DLTs, or discontinuations; AEs were Grade 1–2 and self‑resolving.

Original SEC Filing: Climb Bio, Inc. \[ CLYM \] - 8-K - Jun. 05, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [CLYM.US](https://longbridge.com/en/quote/CLYM.US.md)

## Related News & Research

- [Climb Bio initiates Phase 2 CLYM116 trial in IgA nephropathy in Q3 2026](https://longbridge.com/en/news/295100999.md)
- [Climb Bio Q2 FY26 net loss widens 55.73% to $13.5 million](https://longbridge.com/en/news/295096386.md)
- [Truist Financial Sticks to Its Buy Rating for Climb Bio (CLYM)](https://longbridge.com/en/news/295232158.md)
- [Aquestive reports positive human factors, PK results for Anaphylm epinephrine sublingual film in healthy volunteers](https://longbridge.com/en/news/295396858.md)
- [SANASA fiscal council reviews Q2 2026 interim financial report (ITR)](https://longbridge.com/en/news/295570195.md)